Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Fig. 1

Genome-wide CRISPR/Cas9 knockout screens identify genes associated with ALK inhibitor response. a Schematic of CRISPR/Cas9 knockout screens in the neuroblastoma cell line SH-SY5Y. b Overview of screen results. Negative beta scores indicate depletion of sgRNAs targeting denoted genes during treatment, whereas positive beta scores indicate enrichment. Significant candidate genes (P < 0.01) with highly abundant sgRNAs during treatment are highlighted in red; Pearson correlation coefficient r = 0.896, p < 0.0001 (two-tailed t-test). c Histograms depicting the abundance distribution of all sgRNAs to their log2 fold change (mean ALK inhibitor/mean DMSO) for both ALK inhibitors. The enrichment of sgRNAs targeting NF1 is shown below, with each colored line representing one of the four sgRNAs targeting NF1. The enrichment of sgRNAs is consistent between both ALK inhibitors

Back to article page